Chiltern seeking metabolism expertise for new unit after hiring ex PPD exec

By Dan Stanton contact

- Last updated on GMT

Chiltern seeking metabolism expertise for new unit after hiring ex PPD exec

Related tags: Insulin, Diabetes mellitus type 2, Obesity

Got experience in endocrinology and metabolism indications R&D? Chiltern has added a new offering and says it is looking to hire.

Chiltern’s acquisition of Theorem​ last month strengthened its oncology, biopharma, medical device and diagnostic offerings, creating what the firm said is the largest mid-sized contract research organisation (CRO).

Now the firm says it is expanding its business further to include endocrine and metabolism services through the addition of Randy Anderson as senior vice president of scientific affairs.

“My experience and expertise in strategic program design for endocrine and metabolism products will be a new service offering at Chiltern,”​ Anderson, who has nearly 30 years of industry experience in the industry, told Outsourcing-Pharma.

My hire is synergistic with the recent Theorem acquisition in expanding Chiltern’s capacity for design and execution of endocrinology and metabolism programs.”

For the past five years, Anderson served as Vice President of Global Product Development for Metabolics at PPD, and before that spent twelve years at the Big CRO in senior management roles.

He is now looking to help Chiltern respond to client demand by expanding its clinical services for endocrinology and metabolism, and said the firm is looking for further expertise:

Chiltern is actively hiring management and operations staff with experience in endocrinology and metabolism indications,”​ he told us.

This include: “Type 2 diabetes, type 1 diabetes, diabetes complications, nonalcoholic steatohepatitis, obesity, dyslipidemias, adrenal disorders, thyroid disorders, pituitary disorders, calcium homeostasis disorders, cardiovascular disease prevention, growth disorders, sex androgen dysfunction and other rare metabolic disease indications such as lysosomal storage disorders, Prader-Willi Syndrome and Fabry disease.”

Related news

Show more

Related products

show more

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

Related suppliers

Follow us

Products

View more

Webinars